is the fda stopping compounded tirzepatide Important Update: Phasing Out! 🚨 FDA Moves to Permanently

To ensure patient safety and market dominance, the digital architecture must address the specific physiological demands of GLP-1 therapy

Clinical trial results by dose level The SURMOUNT-1 trial, published in the New England Journal of Medicine, evaluated tirzepatide for weight management in adults with obesity

Together, and using our proprietary NX35 plant-derived exosome technology, they create askin rebound protocol that addresses both surface-level concerns and underlying structure at the cellular level

All PlexusDx medications are produced exclusively in licensed 503A compounding pharmacies (never 503B) and are available to patients in all 50 states